Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
The first two sections of the book discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors, exploring topics such as the in vivo function of CDKs in normal homeostasisand tumor development and the structural biology of CDKs. The third section examines the design, development, and chemistry of small molecule CDK inhibitors, with discussions ranging from the early-stage discovery of new chemical entities with a capacity to inhibit CDKs to late-stage compounds in clinical development. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future development of CDK inhibitors as anticancer agents.
The field of drug development is at a critical point in terms of understanding the availability, advantages, and drawbacks of CDKs as therapeutic targets for small molecules. Providing the most up-to-date, in-depth coverage available in a single volume, Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents surveys the success of the agents developed thus far, the possibility of new routes to more selective inhibitors, and the growing appreciation of critical, therapeutic issues.
476 pages; ISBN 9781420005400
, or download in
Title: Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents
Author: Paul J. Smith; Eddy W. Yue
Commercializing Successful Biomedical Technologies 2008 US$ 44.00 361 pages
Electronics All-in-One For Dummies 2013 US$ 31.99 843 pages